US And Europe Hepatic Veno Occlusive Disease Treatment Market: By Drug Class, Antithrombin III Replacement, Defibrotide, Others), By Distribution Channel and Country Forecast 2020-2031
Us Europe Hepatic Veno Occlusive Disease Treatment Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. The hepatic venous-occlusive disease also known as Sinusoidal Obstruction Syndrome (SOS) is characterized by obstruction of small veins in the liver. In this condition, the blood gets blocked in the small veins, due to the blockage of blood in small veins, blood is congested in the liver which leads to a reduction of blood flow into the liver and damages the hepatic cells. Due to the congestion, the liver gets enlarged and finally causes liver cirrhosis. Hepatic veno-occlusive disease caused due to the long-term use of certain drugs, which can cause serious effects on the liver and during bone marrow and stem cell transplantation. There is no specific treatment for the veno-occlusive disease,
However, it can be treated by normalizing the blood flow in hepatic blood vessels by controlling fibrin deposition and vasculitis. Europe's Hepatic Veno Occlusive Disease Treatment Market is in a nascent stage, as very few drugs are available for the treatment. Healthcare professionals are majorly focussing on alternative treatments to normalize the blood flow in hepatic small veins. Currently, market players are focusing on the development of new drugs for the treatment of hepatic veno-occlusive disease. Acquisitions and mergers, collaborations, and product launches are the key strategies followed by companies to increase their revenue share in the hepatic veno-occlusive treatment market. For instance, in July 2014, Jazz Pharmaceuticals, Plc. inked an agreement with Sigma-Tau Pharmaceuticals, Inc. to acquire rights to Defibrotide in the U.S. and all other countries of the Americas.
An increase in the prevalence of cancer diseases that require chemotherapy and radiotherapy, a rise in the adoption of bone marrow and stem cell transplantation, excessive consumption of alcohol, obesity, and a rise in the prevalence of viral hepatitis are anticipated to fuel the hepatic veno-occlusive disease market. Moreover, increases in R&D activities for the innovation of newer drugs, lifestyle changes, and increases in healthcare expenditure are boosting the hepatic-veno occlusive disease treatment market. However, lack of specific treatment options, a high cost of treatment, and stringent regulations and guidelines for drug approval might hinder the growth of the U.S. And Europe's Hepatic Veno Occlusive Disease Treatment Market.
Europe Hepatic Veno Occlusive Disease Treatment Market has been segmented into U.S. and Europe. U.S. accounted for the significant share in the market owing to increase in the prevalence of various oncology diseases, the sedentary lifestyle which leads to obesity and deposition of fat in blood vessels, and rise in R&D for the innovation of newer drugs. Europe hepatic veno occlusive disease treatment market exhibiting lucrative growth owing to the approval of defibrotide by European Commission, increase in the prevalence of genetic disorders, a rise in prevalence of liver cancer in Germany, Italy, and U.K., and increase in chemotherapy and radiotherapy procedures in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
By Drug Class |
|
|
By Distribution Channel |
|
Download Free Sample Report
Us Europe Hepatic Veno Occlusive Disease Treatment Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The key players of the market are Jazz Pharmaceuticals Plc. (Ireland) Novartis AG (Switzerland) Norgine Pharmaceuticals Ltd. (U.K.).
| 1.Executive Summary |
| 2. Us Europe Hepatic Veno Occlusive Disease Treatment Market Introduction |
| 2.1. Us Europe Hepatic Veno Occlusive Disease Treatment Market - Taxonomy |
| 2.2. Us Europe Hepatic Veno Occlusive Disease Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Distribution Channel |
| 3. Us Europe Hepatic Veno Occlusive Disease Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Us Europe Hepatic Veno Occlusive Disease Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Us Europe Hepatic Veno Occlusive Disease Treatment Market By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Heparin |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Tissue Plasminogen Activators (t-PA) |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Antithrombin III (ATIII) Replacement |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Defibrotide |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Us Europe Hepatic Veno Occlusive Disease Treatment Market By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Hospital Pharmacies |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacies |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Online pharmacies |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 7.2.1.Jazz Pharmaceuticals Plc. (Ireland) |
| 7.2.2.Novartis AG (Switzerland) |
| 7.2.3.Norgine Pharmaceuticals Ltd. (U.K.) |
| 8. Research Methodology |
| 9. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
